NFκB/C1Q SASP Modulation for Synaptic Protection

Target: ? Composite Score: 0.534 Price: $0.53 Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

⚠ No Target Gene Senate Quality Gates →

Quality Report Card click to collapse

C+

Composite: 0.534

Top 79% of 681 hypotheses

T5 Contested

Contradicted by evidence, under dispute

B Mech. Plausibility 15% 0.62 Top 65%

C+ Evidence Strength 15% 0.58 Top 61%

B Novelty 12% 0.68 Top 80%

C+ Feasibility 12% 0.52 Top 63%

B Impact 12% 0.65 Top 67%

C Druggability 10% 0.45 Top 73%

B Safety Profile 8% 0.60 Top 42%

C Competition 6% 0.40 Top 91%

C+ Data Availability 5% 0.55 Top 66%

C+ Reproducibility 5% 0.58 Top 61%

Evidence

4 supporting | 4 opposing

Citation quality: 0%

Debates

0 sessions

No debates yet

Convergence

0.00 F 30 related hypothesis share this target

Hypotheses from Same Analysis (4)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Dose-Response Framework: PINK1/Parkin Mitophagy as the Critical Mediator Linking HBOT Parameters to Tau Clearance

Score: 0.614 | Target: ?

NRF2-Mediated Metabolic Reprogramming: HBOT as Direct NAMPT/SIRT1 Activator for Reverse Senescence

Score: 0.602 | Target: ?

Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion Amplifies SST Interneuron-Targeted Neuromodulation

Score: 0.583 | Target: ?

Oxygen Pressure-Dependent BDNF Cascade: DHHC2/PSD95 Stabilization for Synaptic Rescue

Score: 0.580 | Target: ?

Description

HBOT (2.0 ATA, 60 min daily) suppresses NFκB-dependent IL1β release from senescent microglia, reducing SASP-mediated complement amplification loop (C1Q/C3 cascade) that drives synaptic pruning in AD.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

8 citations 8 with PMID Validation: 0% 4 supporting / 4 opposing

✓ For (4)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 4CLIN 4GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
HBOT attenuates neuroinflammation by reducing IL-1…	Supporting	MECH	-	-	-	-	PMID:29141186	-
SASP modulation through NFκB/IL1B is established a…	Supporting	CLIN	-	-	-	-	PMID:N/A	-
Complement C1Q/C3 mediates synapse loss in AD	Supporting	MECH	-	-	-	-	PMID:N/A	-
Terminal complement pathway activation has been de…	Supporting	MECH	-	-	-	-	PMID:35794654	-
Direct complement inhibition trials (pegcetacoplan…	Opposing	CLIN	-	-	-	-	PMID:N/A	-
Annexon ANX005 Phase 1b showed C1q suppression but…	Opposing	CLIN	-	-	-	-	PMID:N/A	-
Complement activation occurs through multiple path…	Opposing	MECH	-	-	-	-	PMID:N/A	-
Complement-mediated synaptic pruning is most promi…	Opposing	CLIN	-	-	-	-	PMID:N/A	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 4

HBOT attenuates neuroinflammation by reducing IL-1β, TNFα and increasing anti-inflammatory cytokines (IL-4, IL…▼

HBOT attenuates neuroinflammation by reducing IL-1β, TNFα and increasing anti-inflammatory cytokines (IL-4, IL-10) in 3xTg-AD mice

PMID:29141186

SASP modulation through NFκB/IL1B is established as therapeutic strategy

PMID:N/A

Complement C1Q/C3 mediates synapse loss in AD

PMID:N/A

Terminal complement pathway activation has been demonstrated in AD brain

PMID:35794654

✗ Opposing Evidence 4

Direct complement inhibition trials (pegcetacoplan, anti-C1q) have not demonstrated cognitive benefit in AD de…▼

Direct complement inhibition trials (pegcetacoplan, anti-C1q) have not demonstrated cognitive benefit in AD despite strong preclinical rationale

PMID:N/A

Annexon ANX005 Phase 1b showed C1q suppression but no cognitive benefit at 12 weeks

PMID:N/A

Complement activation occurs through multiple pathways (classical, alternative, lectin) beyond microglial SASP

PMID:N/A

Complement-mediated synaptic pruning is most prominent during development; therapeutic window may have passed …▼

Complement-mediated synaptic pruning is most prominent during development; therapeutic window may have passed in symptomatic patients

PMID:N/A

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

Low

0.0000

Events (7d)

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (3)

Paper:29141186

No extracted figures yet

Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.

Acta neuropathologica communications (2022) · PMID:35794654

No extracted figures yet

Paper:N/A

No extracted figures yet

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

Related Hypotheses

Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome

Score: 0.971 | neurodegeneration

LRP1-Dependent Tau Uptake Disruption

Score: 0.954 | neurodegeneration

PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction

Score: 0.936 | neurodegeneration

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration

Score: 0.933 | neurodegeneration

SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis

Score: 0.909 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

NFκB/C1Q SASP Modulation for Synaptic Protection

Hypotheses from Same Analysis (4)

Description

Dimension Scores

✓ Supporting Evidence 4

✗ Opposing Evidence 4

Price History

Clinical Trials (0)

📚 Cited Papers (3)

📓 Linked Notebooks (0)

⚔ Arena Performance

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions

Knowledge Subgraph (0 edges)

Community Feedback